The longitudinal progression trend for GM ICV proportion follows that of a human study of CLN2 disease that showed a decrease in GM is a significant marker for disease progression, with the highest decrease found in the supratentorial region of the brain9,10,58. The gene discussed is TPP1; the disease is glycogen storage disease VI.